244 related articles for article (PubMed ID: 21850662)
1. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
Mughal TI; Radich JP; Van Etten RA; Quintás-Cardama A; Skorski T; Ravandi F; DeAngelo DJ; Gambacorti-Passerini C; Martinelli G; Tefferi A
Am J Hematol; 2011 Sep; 86(9):811-9. PubMed ID: 21850662
[TBL] [Abstract][Full Text] [Related]
2. Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib.
Guilbert-Douet N; Morel F; Le Bris MJ; Berthou C; Morice P; Bourquard P; Braekeleer MD
Leukemia; 2004 Jun; 18(6):1140-2. PubMed ID: 15085159
[No Abstract] [Full Text] [Related]
3. Molecular evidence of transient complete remission after autografting in Ph-/bcr rearranged chronic myelogenous leukaemia.
Lo Coco F; Saglio G; De Fabritiis P; Diverio D; Guerrasio A; Rosso C; Meloni G; Mancini M; Mandelli F
Br J Haematol; 1989 Jun; 72(2):285-6. PubMed ID: 2667624
[No Abstract] [Full Text] [Related]
4. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy.
Quintás-Cardama A; Kantarjian H; Abruzzo LV; Cortes J
Leukemia; 2007 Nov; 21(11):2394-6. PubMed ID: 17690707
[No Abstract] [Full Text] [Related]
5. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia from basics to bedside.
Thijsen S; Schuurhuis G; van Oostveen J; Ossenkoppele G
Leukemia; 1999 Nov; 13(11):1646-74. PubMed ID: 10557038
[TBL] [Abstract][Full Text] [Related]
7. The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia.
Wakim JJ; Tirado CA; Dowell J; Chen W
Cancer Genet; 2012 Mar; 205(3):124-7. PubMed ID: 22469511
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.
Pereira WO; De Carvalho DD; Zenteno ME; Ribeiro BF; Jacysyn JF; Sardinha LR; Zanichelli MA; Hamerschlak N; Jones GE; Pagnano KB; Castro FA; Calle Y; Amarante-Mendes GP
Cell Death Dis; 2017 Oct; 8(10):e3114. PubMed ID: 29022901
[TBL] [Abstract][Full Text] [Related]
9. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
Corsetti MT; Lerma E; Dejana A; Basta P; Ferrara R; Benvenuto F; Vassallo F; Abate M; Piaggio G; Parodi C; Sessarego M; Li Pira G; Manca F; Carella AM
Leukemia; 1999 Jul; 13(7):999-1008. PubMed ID: 10400414
[TBL] [Abstract][Full Text] [Related]
10. Genetic events other than BCR-ABL1.
Neviani P
Curr Hematol Malig Rep; 2014 Mar; 9(1):24-32. PubMed ID: 24407376
[TBL] [Abstract][Full Text] [Related]
11. [BCR-ABL1 negative chronic myeloid leukemia: report of two cases].
Figueroa-Faúndez F; Vidal-Rojas C; Briones-Muñoz V; Chandía-Cabas M
Rev Med Chil; 2022 Mar; 150(3):397-401. PubMed ID: 36156725
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.
Cross NC; Daley GQ; Green AR; Hughes TP; Jamieson C; Manley P; Mughal T; Perrotti D; Radich J; Skoda R; Soverini S; Vainchenker W; Verstovsek S; Villeval JL; Goldman JM
Leukemia; 2008 Nov; 22(11):1975-89. PubMed ID: 19002192
[No Abstract] [Full Text] [Related]
13. How I treat atypical chronic myeloid leukemia.
Gotlib J
Blood; 2017 Feb; 129(7):838-845. PubMed ID: 27899359
[TBL] [Abstract][Full Text] [Related]
14. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
[TBL] [Abstract][Full Text] [Related]
15. DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.
Pawlowska E; Blasiak J
Int J Mol Sci; 2015 Nov; 16(11):27535-49. PubMed ID: 26593906
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
[TBL] [Abstract][Full Text] [Related]
17. Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation.
Saqlain N; Ahmed N
J Coll Physicians Surg Pak; 2016 Nov; 26(11):103-105. PubMed ID: 28666496
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-negative, bcr/abl-positive chronic myelogenous leukemia.
Inokuchi K; Dan K
J Nippon Med Sch; 2001 Aug; 68(4):292-3. PubMed ID: 11505275
[No Abstract] [Full Text] [Related]
19. [The assessment of therapeutic success in chronic myeloid leukemia].
Griesshammer M; Hehlmann R; Heimpel H
Dtsch Med Wochenschr; 1995 Apr; 120(17):620-5. PubMed ID: 7537652
[No Abstract] [Full Text] [Related]
20. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
